Fig. 7: Ferrichrome promotes CD8 + T cell infiltration in pancreatic tumors and improves anti-PD-L1 therapy.
From: Reprogramming of pancreatic adenocarcinoma immunosurveillance by a microbial probiotic siderophore
a Representative histogram comparing MHCII MFIs in M1-like macrophages (gated CD45 + CD11b + Ly6C− Ly6G- F4/80+ MHCII-high) of tumors treated with ferrichrome (cyan) or vehicle (red) as determined by flow cytometry analysis (n = 3 mice). b Flow cytometry analysis of the frequency of (c) total T cells (CD3+) and (d) CD8 + T cells in tumors treated with ferrichrome (blue) or vehicle (maroon) (n = 4 mice). e Schematic representation of combination treatment regimen of ferrichrome and anti-PD-L1 of UN-KC-6141 syngeneic mouse model. Ferrichrome was given five times per week starting at day 3 while anti-PD-L1 (200 µg/mouse) was given twice per week starting at day 5. Tumors were resected at day 26 (n = 5–8). Graph representing mean values of (f) tumor volume at endpoint, (g) tumor weight and (h) tumor volume of individual mice per treatment group. Mean ± SEM shown. *p < 0.05, and **p < 0.01, and ***p < 0.001 as determined by Student’s t test for T cell analysis and one-way ANOVA for combination analysis.
